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Ethnopharmacological relevance: The Zibu Piyin Recipe (ZBPYR) is derived from Zicheng Decoction, a
traditional Chinese medicine formula recorded in the book of Bujuji, written by Wu Cheng in the Qing
dynasty and used for clinical treatment of amnesia. Our aim was to study the effects of Zibu Piyin Recipe
(ZBPYR) fractions on scopolamine-induced learning and memory impairment in the mouse.
Materials and methods: Crude extracts were prepared using various solvents, and individual fractions
produced following D101 macroporous resin column chromatography. The passive avoidance task, step
down test and Morris water maze test were then performed in mice for the evaluation of learning
and memory alterations. The effective fractions were then analyzed using GC–MS and polysaccharide
measurement methods, respectively.
Results: The treatment group latency for the alcohol precipitation from water part (EP) and 95% ethanol
part (95%E) following D101 macroporous resin column chromatography was signiﬁcantly prolonged
when compared to that of the scopolamine treated groups for both the passive avoidance task and step
down test. In the Morris water maze tests, treatment with EP and 95%E resulted in a signiﬁcantly shorter
escape latency time (from the fourth day and the second day) and swimming distance (on the third day
and from the third day) in scopolamine-induced mice. In the memory retention test, treatment with EP
and 95%E dramatically shortened the latency to cross platform location and increased the numbers of
platform location crosses in the scopolamine-induced mice. The polysaccharide content in EP was
determined to be 69.79%. The 95%E was found to mainly contain asarone, α-cadinol, isocalamendiol,
2,4,7,14-tetramethyl-4-vinyl-tricyclo[5.4.3.0(1,8)]tetradecan-6-ol, 3-isopropyl-6,7-dimethyltricyclo
[4.4.0.0(2,8)]decane-9,10-diol, 2-methyl-9-(prop-1- -en-3-ol-2-yl)-bicyclo[4.4.0]dec-2-ene-4-ol, diepice-
drene-1-oxide, 7-methoxy-6-(3- -methyl-2-oxobutyl)-2H-1-benzopyran-2-one and diisooctyl phthalate
when assessed using GC–MS analysis.
Conclusion: These ﬁndings suggest that the polysaccharide and volatile oil present in ZBPYR exhibit
ameliorating effects on scopolamine-induced memory dysfunction.
& 2013 The Authors. Published by Elsevier Ireland Ltd. 
1. Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative
disorder associated with gradual loss in memory which accounting
for about 50% of all dementias (Brookmeyer et al., 2007;
Schonberger et al., 2001), yet its pathophysiology is complex,
and includes the deposition of senile plaques mainly composed
of amyloid beta protein (Aβ) and neuroﬁbrillary tangles in the
brain of patients (Armstrong, 2006; Portelius et al., 2006),
abnormalities of cholinergic, glutamatergic, adrenergic, serotoner-
gic and dopaminergic neurotransmission, and the potential invol-
vement of oxidative stress and inﬂammation (Cummings, 2004).
Cholinergic hypofunction is thought to be directly related to the
severity of cognitive dysfunction and memory loss in AD patients
(Schliebs and Arendt, 2006). This hypothesis has formed the basis
of the development of acetylcholinesterase inhibitors (AChEi), the
current treatment prescribed in AD patients. AChEi prolong the
action of acetylcholine in the neuronal synapses by preventing its
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breakdown. This treatment strategy results in improvement to
cognition, mood and behavior (Mount and Downton, 2006).
Despite the reported beneﬁts of AChEi treatment on the progres-
sion of AD, its use is limited due to its severe side effects (Casey
et al., 2010). The identiﬁcation of further, more effective treat-
ments requires a greater understanding of the underlying physio-
logical mechanisms, and the development of multi-targeted drugs
as a result of innovative approaches (Mucke, 2009).
Chinese herbal medicines have been widely used for thousands
of years in China and other Asian countries. In the clinical practice
of traditional Chinese medicine (TCM), modiﬁcation of an original
formula by adding or substituting herbs in accordance with a
patient's condition to enhance the efﬁcacy of the original formula
is commonly undertaken. The vast majority of regular Chinese
medicine use is not associated with any serious side effects.
Furthermore, through multi-component, multi-pathway and
multi-target regulation, TCM drugs may exhibit signiﬁcant advan-
tages that single-component drugs are unable to in the treatment
of multifactor, complex chronic diseases such as AD. Speciﬁc
formulas of traditional Chinese herbal medicines have been
reported previously to be effective against numerous cognitive
disorders (Kou et al., 2005; Qiao et al., 2006; Yun et al., 2007).
Zicheng soup, a classic formula of traditional Chinese medicine
(TCM), has been described in a TCM monograph Bujuji written by
Wu Cheng, a distinguished physicians in China Qing Dynasty
(A.D.1644–1912). According to clinical experiences and therapeutic
principles, the Zibu Piyin Recipe (ZBPYR) was developed by
Professor Libin Zhan from Zicheng soup to enhance the effects of
tonifying spleen, beneﬁting intelligence and soothing the nerves.
Our previous experimental studies have conﬁrmed that ZBPYR
protects nerves and improves the learning and memory abilities of
experimental animals (Zhan et al., 2007a, 2007b, 2009, 2011; Shi
et al., 2011). For example, ZBPYR is able to maintain the normal
morphology of dendritic spines (Zhan et al., 2007a), inhibit
endoplasmic reticulum stress and damage of mitochondria
(Zhan et al., 2007b), block the serum-inducible kinase (SNK) and
spine-associated Rap GTPase-activating protein (SPAR) pathway
and regulate the expression of N-methyl-D-aspartate receptor
(NMDAR) to protect the neurons induced by Aβ (Zhan et al.,
2009), increase endoplasmic reticulum stress-mediated survival
pathways of unfolded protein response (Zhan et al., 2011) and
ameliorate diabetes-associated cognitive decline in proteomic
analysis (Shi et al., 2011). ZBPYR treatment has been proven to
protect nerve damage and improve the learning and memory
abilities of experimental animals. However, the precise component
of ZBPYR that plays the pivotal role in these processes remains
unclear. In the present study, we separated ZBPYR into seven
fractions that we termed water decoction (WD), the water and 75%
ethanol extraction fraction (WE), EP, alcohol supernatant from
water part (ES), the 40% ethanol part (40%E), the 75% ethanol part
(75%E) and 95%E following D101 macroporous resin column
chromatography, in order to identify the active fraction. Based
on behavior and chemical analysis research, we ascertained that
the active fractions of ZBPYR were the EP and 95%E fractions that
were found to mainly contain polysaccharide and volatile oil,
respectively. These fractions were then utilized to study the
efﬁcacy of ZBPYR in ameliorating learning and memory perfor-
mance in scopolamine-induced amnesia in mice.
2. Materials and methods
2.1. Animals
Male Kunming mice weighing 2072 g were used in the
current study. The mice were initially acclimatized to the experi-
mental housing conditions and animal handlers for 3 days prior to
all experiments in order to minimize handling stress during the
test. The animals were maintained on a 12 h light/dark cycle with
lights on from 07:00 to 19:00 h daily, and were fed water and
standard laboratory food ad libitum. All experimental procedures
were conducted in accordance with the guidelines for the use of
experimental animals and were approved by the Institutional
Review Committee on Animal Care and Use at the Experimental
Animal Center of Dalian Medical University (Certiﬁcate of Con-
formity: SCXK (Liao) 2008-0002).
2.2. Chemicals and reagents
Scopolamine hydrobromide (Scop) was obtained from Shang-
hai Harvest Pharmaceutical Co., Ltd. D101 macroporous resin was
purchased from Tianjin Pesticide Factory. All remaining reagents
were purchased from Dalian Shenlian Chemical Reagent Co., Ltd.
2.3. Sample preparation
ZBPYR was consisted of 12 herbal materials including Ginseng,
Chinese yam, Indian buead, white peony root, red sage root, white
hyacinth bean, hindu lotus seed, grassleaf sweetﬂag rhizome,
thinleaf milkwort root, sandal wood, red tangerine peel and
licorice root, which were purchased from the Yunnan hay sources
Pharmaceutical Co., Ltd. (Yunnan, China) and authenticated by
associate professor Yunpeng Diao (College of Pharmacy, Dalian
Medical University) (Table 1). The voucher specimens were
deposited at the herbarium of the Academy of Integrative Medi-
cine, Dalian Medical University. The extracts of ZBPYR were
obtained as followed: 164.5 g of twelve powdered herbal materials
was subjected to reﬂux extraction with water (1316 ml) and then
75% ethanol (1316 ml) for 2 h to obtain the water decoction
(WD, 29.93 g) and the water and 75% ethanol extraction fraction
Table 1
The ingredients and botanical origins of Zibu-Piyin Recipe (ZBPYR).
Chinese name Botanical name Common name Weight (g) Voucher numbers
Hong-Shen Panax ginseng C. A. Meyer Red ginseng 30 ZBPYR01-110524
Shan-Yao Dioscorea opposite Thunb. Chinese yam 15 ZBPYR02-110524
Fu-Ling Poria cocos (Schw.) Wolf Indian buead 15 ZBPYR03-110524
Bai-Shao Paeonia lactiﬂora Pall. White peony root 15 ZBPYR04-110524
Dan-Shen Salvia miltiorrhiza Bge. Red sage root 12 ZBPYR05-110524
Bai-Bian-Dou Dolichos lablab L. White hyacinth bean 15 ZBPYR06-110524
Lian-Zi Nelumbo nucifera Gaertn. Hindu lotus seed 20 ZBPYR07-110524
Shi-Chang-Pu Acorus gramineus Soland. Grassleaf sweetﬂag rhizome 10 ZBPYR08-110524
Yuan-Zhi Polygala tenuifolia Willd. Thinleaf milkwort root 10 ZBPYR09-110524
Tan-Xiang Santalum album Linn. Sandal wood 4.5 ZBPYR10-110524
Ju-Hong Citrus maxima (Burm.) Merr. cv. Tomentosa Red tangerine peel 9 ZBPYR11-110524
Gan-Cao Glycyrrhiza uralensis Fisch. Licorice root 9 ZBPYR12-110524
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(WE, 45.55 g). 40 g of WE was then dissolved in 1000 ml of
distilled water and subjected to D101 macroporous resin to yield
the 40% ethanol (40%E, 4.67 g), 75% ethanol (75%E, 1.57 g), 95%
ethanol (95%E, 0.40 g) and water components (Fig. 1). The water
soluble part was then concentrated to 500 ml, and three times the
volume of 95% ethanol added to obtain the supernatant (ES, 7.33 g)
and precipitate (EP, 17.40 g).
95%E (10 mg) was then ultrasonically extracted with 2 ml metha-
nol for 15 min. The extraction was ﬁltered through a 0.22 μm sterile
ﬁlter prior to use. 1 μl of this solution was then injected into the gas
chromatography–mass spectrometry (GC/MS).
2.4. Experimental procedures
The random number table was used to divide the experimental
mice into nine groups termed (1) Scop () control (n¼7), (2)
Scop (þ) (n¼7), (3) ScopþWD (n¼7), (4) ScopþWE (n¼7),
(5) ScopþES (n¼7), (6) ScopþEP (n¼7), (7) Scopþ40%E (n¼7),
(8) Scopþ75%E (n¼7) and (9) Scopþ95%E (n¼7). The ScopþWD,
ScopþWE, ScopþES, ScopþEP, Scopþ40%E, Scopþ75%E and
Scopþ95%E groups received the various polar components via
administration of 0.4637 g of the raw medicinal herbs in 0.14 ml
water per 10 g of body weight for 15 days. The Scop() control
and Scop(þ) groups were administrated 0.14 ml saline per 10 g for
15 days. Scopolamine (2 mg/kg, ip) was given to all Scop groups
from the seventh day, and the same volume of saline (ip) was
given to the control groups.
2.5. Passive avoidance task
Passive avoidance performance was carried out in two identical
light and dark square boxes (121012 cm, respectively). The
apparatus was illuminated by a 50 w lamp placed 1 m above the
boxes. Each test involved two separate trials, a training trial and a
test trial. For the training trial, the mice were initially placed in the
light chamber. When the mouse entered the dark compartment, a
0.5 mA electrical shock of 3 s in duration was delivered through
the stainless steel rods. The latency times for the mice that had
entered the dark compartment were measured with a stopwatch.
A test trial was performed 24 h after the training trial, and latency
times to re-enter the dark chamber were measured up to 300 s.
ZBPYR, its different polar parts (0.4637 g raw medicinal herbs/
10 g, p.o.) or vehicle (same volume of saline) solution were
administered to the mice 30 min prior to the acquisition trials.
Each acquisition trial was carried out 10 min after a single
scopolamine treatment (2 mg/kg, i.p.).
2.6. Step-down test
Mice were housed in a dimly-lit room for at least 30 min prior
to the experiments. The inhibitory avoidance training apparatus
was composed of a plastic box (121218 cm), with an elevated
rubber platform (4.84.84.5 cm) placed on the left side wall of
the training box apparatus, the ﬂoor of which was made of parallel
0.1 cm-caliber stainless steel bars spaced 0.5 cm apart. On the ﬁrst
training day, mice were exposed to a 5 min learning course, during
which they were permitted to move freely throughout the
chamber before being placed on the platform. If the animals
stepped down from the platform (error trial), they were exposed
to an electric foot shock (36 V, AC). After 24 h, latency was
assessed again and recorded as the learning grade (latency), which
was taken as a measure of memory retention.
Drug administration was identical to that of the passive avoid-
ance task (see Section 2.5).
2.7. Morris water maze
The apparatus consisted of a circular pool (35 cm in height and
100 cm in diameter) ﬁlled with 2671 1C water. A clear Plexiglas
platform (10 cm high8 cm diameter) was submerged 1 cm below
the water surface. The pool was divided into four equal quadrants
and each quadrant was marked by a different visual cue. The
platform was randomly placed in one quadrant for the duration of
the experiment. On the ﬁrst day, mice were allowed a 120 s
habituation session in the pool without the platform. In the following
4 days, each rat received four 120 s learning trials with the platform,
with 60 s resting periods between trials. For each learning trial, mice
were placed into the water facing the pool wall at one of four points
of entry. The escape latency, the time required to locate the
submerged platform, was recorded for each trial. If the mice were
unable to locate the platform within 120 s, it was led to the platform
and allowed to rest for 60 s. The escape latency in these cases was
recorded as 120 s. After the completion of the learning trials, the
platform was removed from the pool. Each mouse was then
subjected to a 120 s memory retention test, in which the amount
of time and frequency the mouse spent swimming in the same
quadrant as the platform had previously been hidden was recorded.
Drug administration was identical to that of the passive avoid-
ance task (see Section 2.5).
2.8. Statistical analysis
In the behavior testing, as the data do not meet the normal
distribution, a nonparametric test (Kruskal–Wallis Test) is used to
WE (40g)
D101 macroporous resin eluted using water, 40%,  
75%, 95% ethanol, respectively
Water 40% E (4.67g) 75% E (1.57g) 95% E (0.40g)
three times volume of 95% ethanol added 
EP (17.40g) ES (7.33g)
dissolved in 1000 ml distilled water
concentrated to 500ml
Fig. 1. Preparation of different polar fractions from ZBPYR.
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evaluate the difference between all groups, followed by Mann–
Whitney's U-test (two-tailed) to compare treatment between two
groups. Comparisons between training and test sessions were
done with Wilcoxon test. Statistical analyses were performed
using SPSS 15.0 software (SPSS Inc., Chicago, Illinois, USA). po0.05
was considered statistically signiﬁcant.
2.9. Polysaccharide measurement
The polysaccharide content in EP was measured using sulfuric
acid-anthrone colorimetry. Maximum absorption of standard and
EP measurements were performed on a UV-9100 spectrophot-
ometer. For these experiments a glucose calibration curve was ﬁrst
prepared. Accurately measured 0.0, 0.01, 0.02, 0.03, 0.04 and
0.05 ml of glucose standard solution was added to stoppered test
tubes and double distilled water (DDW) added to 1 ml. The tubes
were then placed in an ice bath, and 4 ml of sulfuric acid-anthrone
reagent (50 mg anthrone in 100 ml sulfuric acid) added to each
tube. The tubes were then re-plugged and agitated, incubated in a
100 1C water bath for 15 min and cooled to room temperature. The
absorbance was then recorded at a wavelength of maximum
absorption. The calibration curve was constructed according to
absorbance unit and glucose concentration.
For polysaccharide measurement, the EP was placed in a 50 ml
volumetric ﬂask and DDWadded to the scale line. Then, based on the
calibration curve of glucose mentioned above, the monosaccharide
concentration was obtained and the polysaccharide content in EP
calculated. This study was also undertaken to deﬁne the linearity,
sensitivity, precision and reproducibility of the experiment.
2.10. GC–MS analysis
The GC/MS analysis was performed using an Agilent gas 7890
chromatography instrument, combined with an Agilent-5975 C
mass spectrometer equipped with an electron ionization (EI)
and quadrupole analyzer. 95%E were separated using a HP-5ms
(HP-5MS 30 m250 μm id., 0.25 μm ﬁlm thickness, Agilent, USA)
containing a 5% Phenyl Methyl Silox capillary column. The tem-
peratures of the ion source and interface were set at 230 1C and
280 1C, respectively. The injector temperature of 300 1C was
employed, and the mass scan range was from 30 to 1000 amu.
The electron energy was set at 70 eV. The oven temperature was
programmed to hold at 100 1C for 3 min and then increase to
300 1C for 15 min. The total run time was 38 min.
3. Results
3.1. Passive avoidance task
The step-through latency of Scop-treated mice in the passive
avoidance task was signiﬁcantly shorter than that of vehicle-
treated control mice (Fig. 2, po0.01). The effects of pre-training
administration of WD, WE, ES, EP, 40%E, 75%E and 95%E on
retention latencies which were shortened by Scop are also shown
in Fig. 2. The shorter step-through latency was signiﬁcantly
reversed by WE, WD, EP and 95%E administration, as compared
to that of the Scop-treated group (po0.01). Meanwhile, as
compared to the vehicle-treated control group, only pre-
treatment with 95%E caused no signiﬁcant difference in the
retention latency (p40.05).
3.2. Step-down test
The step-down latency of Scop-treated mice in the step-down
test was signiﬁcantly shorter than that of vehicle-treated control
mice (Fig. 3, po0.01). The effects of pre-training administration of
WD, WE, ES, EP, 40%E, 75%E and 95%E on retention latencies which
were shortened by Scop are also shown in Fig. 3. The shorter step-
down latency was signiﬁcantly reversed by WD, WE, EP and 95%E
administration, as compared to that of the Scop-treated group
(po0.01). However, as compared to the vehicle-treated control
group, only pre-treatment with WE caused no signiﬁcant differ-
ence in the retention latency (p40.05).
3.3. Morris water-maze task
In the Morris water maze task, the Scop-treated group exhib-
ited longer escape latencies and swimming distance throughout
the training days than the control group (Fig. 4A and B, po0.01).
From the second day, 95%E administration signiﬁcantly shortened
the escape latencies prolonged by Scop treatment (Fig. 4A
po0.05), meanwhile, as compared to the vehicle-treated control
group, pre-treatment with 95%E caused no signiﬁcant difference in
the retention latency (p40.05). WE signiﬁcantly shortened the
swimming distance prolonged by Scop treatment (Fig. 4B,
Fig. 2. The effects of a single administration of the different polar parts of ZBPYR on
Scop-induced learning and memory impairment in the passive avoidance task.
Each bar and box indicates the median and interquartile range, respectively (n¼7
per group). npo0.05 vs Scop treated group, nnpo0.01 vs Scop treated group.
▲po0.05 vs control group, ▲▲po0.01 vs control group.
Fig. 3. The effects of a single administration of the different polar parts of ZBPYR on
Scop-induced learning and memory impairment in the Step-down test. Each bar
and box indicates the median and interquartile range, respectively (n¼7 per
group). npo0.05 vs Scop treated group, nnpo0.01 vs Scop treated group.
▲po0.05 vs control group, ▲▲po0.01 vs control group.
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po0.05), meanwhile, as compared to the vehicle-treated control
group, pre-treatment with WE caused no signiﬁcant difference in
the swimming distance (p40.05) except the ﬁfth day (po0.05).
From the third day, WE signiﬁcantly shortened the escape laten-
cies prolonged by Scop treatment (Fig. 4A, po0.01), meanwhile, as
compared to the vehicle-treated control group, pre-treatment
with WE caused no signiﬁcant difference in the retention latency
(p40.05). WD and 95%E signiﬁcantly shortened the swimming
distance prolonged by Scop treatment (Fig. 4B, po0.05), however,
as compared to the vehicle-treated control group, pre-treatment
with WD and 95%E also caused signiﬁcant difference in the
swimming distance (po0.05). From the Fourth day, EP signiﬁ-
cantly shortened the escape latencies prolonged by Scop treatment
(Fig. 4A, po0.01), meanwhile, as compared to the vehicle-treated
control group, pre-treatment with EP caused no signiﬁcant differ-
ence in the swimming distance (p40.05). Moreover, WD signiﬁ-
cantly shortened the escape latencies prolonged by Scop treatment
only on the third day (Fig. 4A, po0.05), and as compared to the
vehicle-treated control group, pre-treatment with WD caused no
signiﬁcant difference in the retention latency (p40.05). EP and
75%E signiﬁcantly shortened the swimming distance prolonged by
Scop treatment only on the third day (Fig. 4B, po0.05), and as
compared to the vehicle-treated control group, pre-treatment
with EP caused no signiﬁcant difference in the retention latency
(p40.05). 40%E signiﬁcantly shortened the swimming distance
prolonged by Scop treatment only on the ﬁfth day (Fig. 4B,
po0.05), but as compared to the vehicle-treated control group,
pre-treatment with 40%E caused signiﬁcant difference in swim-
ming distance (po0.05).
On the day following the ﬁnal training trial sessions, latency to
cross the platform location for the Scop-treated group was
signiﬁcantly longer than those of the vehicle-treated control
group (Fig. 4C, po0.05). WD, WE, EP and 95%E administration
signiﬁcantly shortened the latency to cross the platform location
Fig. 4. The effects of a single administration of the different polar parts of ZBPYR on the latency time (A), swimming distance (B) in the training trial sessions, the latency to
cross platform locations (C) and the number of platform location crosses (D) in the trial session of the Morris water maze task in Scop-induced learning and memory
impaired mice, the results were expressed with medians and interquartile range (n¼7 per group). npo0.05 vs Scop treated group, nnpo0.01 vs Scop treated group. #po0.05
vs control group, ##po0.01 vs control group.
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prolonged by Scop treatment (Fig. 4C po0.05), meanwhile, as
compared to the vehicle-treated control group, pre-treatment
with them caused no signiﬁcant difference (p40.05). WD,
WE, EP, 75%E and 95%E signiﬁcantly increased the number of
platform location crosses decreased by the Scop treatment (Fig. 4D
po0.05) and as compared to the vehicle-treated control group,
pre-treatment with WD, WE, 95%E caused no signiﬁcant difference
(p40.05).
The Wilcoxon test indicated that the evaluation of learning and
memory procedures by escape latency in the Morris water maze
showed all groups of mice reduced the time necessary to reach the
hidden platform (escape) or platform position (test) during the
acquisition period from day 2 to the testing day (Fig. 5,
Wilcoxon test).
3.4. Polysaccharide content
The wave-length was set to 620 nm in accordance to the
absorption maximum of glucose and EP. The glucose calibration
equation was Y¼1.566Xþ0.0654, R2¼0.9948, which revealed a
good linear relationship between 1.0 and 5.0 mg/ml glucose
content and the absorbance unit. The polysaccharide content in
EP was 69.79% according to glucose calibration equation and
absorbance unit. This method was shown to be convenient,
reproductive and accurate according to the results of the precision
(RSD¼0.40%), reproducibility (RSD¼1.70%, 3.44%) and recovery
(RSD¼1.81%) experiments.
3.5. GC–MS determination
Investigation of the electron impact (EI) mass spectral database
and chemical ionization (CI) mass spectra validation, identiﬁed
and structurally conﬁrmed 10 different compounds. The relative
content in percentage was calculated using the Area Normalization
Method. These compounds are listed in Table 2.
4. Discussion
It is well known that scopolamine, a non-selective centrally
acting muscarinic receptor antagonist, impairs learning and mem-
ory in both rodents and humans. This experimental model of
memory impairment has been extensively used in research to
screen for drugs with potential therapeutic value in dementia (El-
Sherbiny et al., 2003; Saxena et al., 2007; Sharma et al., 2010).
Improvement of learning and memory impairment are usually
evaluated through the Passive avoidance task, Step-down test and
Morris water maze task (Kim et al., 2007; Gacar et al., 2011; Utkan
et al., 2012).
TCM is usually prepared from aqueous extracts of a few herbs
that may contain hundreds of different chemical compounds.
Some of these compounds are useless, or may even prove toxic
and should be eliminated. Thus, the discovery of active fractions
helps ensure the safety and availability of TCM. Many studies have
shown that polysaccharides (Pan et al., 2007; Fu et al., 2009; Gao,
et al., 2012), saponins (Jin et al., 1999) and volatile oils (Hritcu
et al., 2012) are present in the active fractions that help improve
learning and memory impairment.
Based on the results of our previous research, ZBPYR had been
proven to be effective in the amelioration of learning and memory
defects in animals and patient models. The present study inves-
tigated the effects of WD, WE, 40%E, 75%E, 95%E, ES and EP
fractions of ZBPYR on scopolamine-induced memory impairment
in mice using the three different learning and memory tasks
described above. The results of these behavioral studies indicate
that administration of all fractions from ZBPYR could ameliorate
learning and memory impairment with different degree, in
which WE demonstrate better ameliorating effects than WD on
the scopolamine-induced memory dysfunction, EP and 95%E
from WE seems to be the effective fractions. In combination
with the results of polysaccharide content determination and
GC–MS analysis, the active fractions were presumed to be poly-
saccharide and volatile oil. However, as the components are
very complicated, further research is required to precisely deﬁne
the basis of this novel drug development from traditional
Chinese medicines.
From the results of GC–MS analysis, the presence of diisooctyl
phthalate in 95% E attracted our attentions. As we know, phthalate
as noxious substances, are forbidden to use in food or living goods.
However some herbal medicines contain phthalate, for example
red sage root (Dian et al., 2006) and white peony root (Zhai et al.,
2009) in our formula. So the limit test on phthalate is also needed
for traditional medicine.
Fig. 5. The effects of a single administration of the different polar parts of ZBPYR on
the latency time in the training and test sessions of the Morris water maze task in
Scop-induced learning and memory impaired mice, the results were expressed
with medians7 interquartile range (n¼7 per group). #po0.05 vs the respective
test session (Wilcoxon test).
Table 2
Results after GC–MS analysis of 95%E.
No. Chemical name Mass fragments Relative content (%)
1 β-asarone 208, 193, 165, 91, 69 22.007
2 α-cadinol 204, 161,121, 95, 43 2.446
3 α-asarone 208, 193, 165, 91, 69 15.208
4 Isocalamendiol 223, 202, 159, 81 6.602
5 2,4,7,14-tetramethyl-4-vinyl-tricyclo[5.4.3.0(1,8)]tetradecan-6-ol 149, 135, 121, 108, 97 3.176
6 3-isopropyl-6,7-dimethyltricyclo[4.4.0.0(2,8)]decane-9,10-diol 220, 177, 149, 121 1.066
7 2-methyl-9-(prop-1-en-3-ol-2-yl)- bicyclo[4.4.0]dec-2-ene-4-ol 218, 203, 185, 157, 143 1.563
8 Diepicedrene-1-oxide 220, 205, 135, 121, 109 5.877
9 7-methoxy-6-(3-methyl-2-oxobutyl)- 2H-1-benzopyran-2-one 260, 189, 161, 131, 103 6.754
10 Diisooctyl phthalate 279, 167, 149, 104 5.225
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